Catalyst Database
Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.
Ticker
Drug | Disease (links)
Stage (next event)
Catalyst Date
ENTA
Phase 2
Zelicapavir (EDP-938)
RSV (Respiratory Syncytial Virus)
Q3 2025
RSVHR, RSVPEDs, RSVTx trials. 5/6/24- RSVPEDs: Study near completion. Younger age cohort partially enrolled. RSVHR: Enrollment ongoing. 12/9/24- First-in-Pediatrics topline results reported. 2/10/25- Topline Results for RSVHR in Q3 2025.
Data readout
ARQT
PDUFA
ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inihibitor)
Atopic Dermatitis (2 -5 yrs)
October 13, 2025
INTEGUMENT-PED trial. 5/2/23- Complete enrollment; 9/19/23- Met all the primary and secondary endpoints. To submit sNDA for the population after roflumilast cream approval. 6/5/24- Safety & efficacy data (poster) at Eczema Conference on 8th of June. 8/28/24- Reported long-term safety and tolerability data. 12/16/24- sNDA submission. 2/26/25- sNDA accepted. PDUFA target action date October 13, 2025.
Approval decision
Meeting
Biomedical meeting
Society for Immunotherapy of Cancer (SITC)
Cancer
November 5-9, 2025
SITC meeting dates: Nov 5-9, 2025. See the full SITC conference page: https://www.sitcancer.org/2025/home
Meeting dates
Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20


